At a Glance
- Company: XCath Medical
- Location: US-based (neurointerventional focus)
- Deal value: $30M Series C (total raised $92M)
- Focus area: Endovascular surgical robotics for stroke/aneurysms
- Next steps: Pivotal trials, regulatory clearance
What happened?
XCath Medical announced a $30 million Series C financing on 12 March 2026, co-led by Crescent Enterprises and serial robotics entrepreneur Dr. Fred Moll (Intuitive Surgical, Auris). The oversubscribed round brings total funding to $92 million for its robotic platform enabling single-operator neuroendovascular procedures.
Why does it matter?
Neurovascular interventions treat 1M+ annual stroke/aneurysm cases but rely on manual catheters with high radiation exposure and operator fatigue. XCath’s robot offers 3D navigation, force sensing and 1mm precision, potentially reducing complications while enabling telesurgery in underserved regions.
Who’s behind it?
XCath develops micro-robotics for endovascular access; Dr. Moll’s involvement validates platform. CEO David Riggs leads commercialisation toward FDA submission.
How was it achieved?
XCath’s platform uses magnetically-steered microcatheters with haptic feedback; first-in-human procedures completed with safety/efficacy comparable to manual. Funds support pivotal IDE trial enrollment.
What’s next?
Pivotal neurovascular trials start Q4 2026; FDA clearance targeted 2028. Expand platform to coronary/peripheral vascular applications.
What are people saying?
Dr. Moll: “XCath solves… precision challenge.” Riggs: “Transformational capital… first robotic thrombectomy.”